Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|October 29, 2021
Daily Medication Pearl: Atogepant (Qulipta) for Episodic Migraine
Author(s)Saro Arakelians, PharmD
Atogepant is indicated for the preventive treatment of episodic migraine in adults.
Advertisement
Medication Pearl of the Day: Atogepant (Qulipta)
Indication: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
Insight:
- Dosing: The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. Severe renal impairment or end-stage renal disease take 10 mg once daily.
- Dosage form: Tablets 10 mg, 30 mg, and 60 mg
- Adverse events (AEs): The most common AEs (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
- Mechanism of action: Atogepant is a CGRP receptor antagonist.
- Manufacturer: AbbVie
Sources:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5